Format

Send to

Choose Destination
Br J Cancer. 2015 Mar 3;112(5):777-82. doi: 10.1038/bjc.2015.6. Epub 2015 Jan 22.

MicroRNA in radiotherapy: miRage or miRador?

Author information

1
1] Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5 [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7.
2
1] Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5 [2] Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5T 1P5 [3] Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
3
1] Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5 [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7 [3] Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada M5T 1P5 [4] Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.

Abstract

At least half of all cancer patients will receive radiation therapy. Tumour radioresistance, or the failure to control certain tumours with this treatment, can result in locoregional recurrence; thus there is great interest in understanding the underlying biology and developing strategies to overcome this problem. The expanding investigation of microRNA in cancer suggests that these regulatory factors can influence the DNA damage response, the microenvironment and survival pathways, among other processes, and thereby may affect tumour radioresistance. As microRNA are readily detectable in tumours and biofluids, they hold promise as predictive biomarkers for therapy response and prognosis. This review highlights the current insights on the major ways that microRNA may contribute to tumour radiation response and whether their levels reflect treatment success. We conclude by applying the potential framework of future roles of miR in personalised radiotherapy using prostate cancer clinical management as an example.

PMID:
25611301
PMCID:
PMC4453960
DOI:
10.1038/bjc.2015.6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center